Noteworthy, Maziarz and co-workers43 performed a post-hoc analysis based on data from the randomized trial of plerixafor + G-CSF vs. placebo + G-CSF in NHL patients. The gene discussed is CSF3; the disease is non-Hodgkin lymphoma.